Researchers examined data from more than 21,000 patients treated from 1997 to 2018, publishing their findings in the Journal of the American Heart Association.

“These findings are highly pertinent in a clinical setting," researchers explained. 

Revisit some of the year's biggest trends in the diagnosis, treatment and prevention of cardiovascular disease. 

The popular SGLT2 inhibitor, sold under the brand name Farxiga, is approved by the FDA to treat heart failure, type 2 diabetes and CKD. Recent data on its ability to affect the symptoms of heart failure patients have been inconsistent. 

New AFib recommendations from the American College of Cardiology and American Heart Association covered significant ground—but there is still much more to learn, experts explained. 

While the therapy has been successfully tested on animals in the past, this study represents the first time it has been used on humans.

“Marijuana use isn’t without its health concerns, and our study provides more data linking its use to cardiovascular conditions," one researcher said. 

Novo Nordisk shared initial results from the SELECT trial back in August, but now the full analysis—which includes data from more than 17,000 patients—has been published in The New England Journal of Medicine.